Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cardiotoxicity in patients treated with bevacizumab is potentially reversible.

× No keyword cloud information.

9 in total

1. Use of bevacizumab as a first-line treatment for metastatic breast cancer.

Authors: L Manso; F Moreno; R Márquez; B Castelo; A Arcediano; M Arroyo; A I Ballesteros; I Calvo; M J Echarri; S Enrech; A Gómez; R González Del Val; E López-Miranda; M Martín-Angulo; N Martínez-Jañez; C Olier; P Zamora
Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677

2. Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer.

Authors: Haruka Chino; Yosuke Amano; Yasuhiro Yamauchi; Jun Matsuda; Norihiko Takeda; Goh Tanaka; Daiya Takai; Takahide Nagase
Journal: J Thorac Dis Date: 2016-09 Impact factor: 2.895

Review 3. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors: Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal: Clin Biochem Date: 2014-11-07 Impact factor: 3.281

4. Myocardial dysfunction caused by abemaciclib: a case report.

Authors: Takuya Oyakawa; Lina Inagaki; Zhensheng Hua; Aya Ebihara; Toshimi Takano; Shinji Ohno; Taro Shiga
Journal: Int Cancer Conf J Date: 2021-07-17

5. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.

Authors: John D Groarke; Toni K Choueiri; David Slosky; Susan Cheng; Javid Moslehi
Journal: Curr Treat Options Cardiovasc Med Date: 2014-09

Review 6. Evaluation and management of patients with heart disease and cancer: cardio-oncology.

Authors: Joerg Herrmann; Amir Lerman; Nicole P Sandhu; Hector R Villarraga; Sharon L Mulvagh; Manish Kohli
Journal: Mayo Clin Proc Date: 2014-09 Impact factor: 7.616

Review 7. Cardiotoxicity and oncological treatments.

Authors: Axel Schlitt; Karin Jordan; Dirk Vordermark; Jürgen Schwamborn; Thorsten Langer; Christoph Thomssen
Journal: Dtsch Arztebl Int Date: 2014-03-07 Impact factor: 5.594

Review 8. Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer.

Authors: Magdalena Zaborowska-Szmit; Maciej Krzakowski; Dariusz M Kowalski; Sebastian Szmit
Journal: J Clin Med Date: 2020-04-27 Impact factor: 4.241

9. Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma.

Authors: Zhiying Fu; Jun Zhu; Wen Zheng; Weiping Liu; Zhitao Ying; Yan Xie; Xiaopei Wang; Ningjing Lin; Meifeng Tu; Lingyan Ping; Lijuan Deng; Chen Zhang; Ning Ding; Yuqin Song
Journal: Cancer Cell Int Date: 2014-01-18 Impact factor: 5.722

9 in total